High-grade Glioma Clinical Trial
Official title:
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
1. To retrospectively explore the feasibility of multi-dimensional heterogeneity imaging features of MRI in predicting the status of key gene mutations in high-grade gliomas; 2. To prospectively explore the correlation between multi-dimensional heterogeneous MRI image features and prognosis of high-grade glioma patients.
Glioblastoma, the most prevalent primary intracranial tumor, is characterized by its formidable therapeutic resistance, primarily attributed to its intrinsic heterogeneity. This heightened heterogeneity is not solely confined to inter-tumoral variations across different individuals but also encompasses considerable intratumoral diversity. The pervasive notion among the scientific community posits that this intratumoral heterogeneity substantiates an endogenous mechanism for drug resistance, thereby exerting substantial influence upon the design of clinical trials, prognostic prediction, and patient outcomes. Preceding methodologies for assessment are beleaguered by a constellation of challenges, impeding precise evaluation of global tumor heterogeneity and necessitating innovative modalities to surmount this impasse. MRI imaging, endowed with non-invasiveness and user-friendliness, surmounts the biases of single-point sampling, enabling comprehensive and dynamic appraisal of glioblastomas. Notably, high-grade gliomas exhibit pronounced microenvironmental pressure selectivity and adaptability, akin to species occupation within distinct ecological niches. This phenomenon, termed "habitat," manifests as a visual representation of the tumor's spatial distribution and temporal evolution, thus facilitating real-time, longitudinal monitoring. Given the substantial imaging heterogeneity inherent to glioblastomas, they stand as an opportune subject for habitat imaging techniques compared to their neoplastic counterparts. The present investigation endeavors to leverage multi-center, multi-dimensional MRI spatial heterogeneity analysis to predict pivotal genes germane to prognosis and therapy in high-grade gliomas, ultimately constructing a stratified prognostic model for afflicted patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02305056 -
Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)
|
Phase 1 | |
| Recruiting |
NCT04299191 -
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT00548938 -
Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
|
Phase 2 | |
| Recruiting |
NCT05610891 -
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
|
Phase 1 | |
| Completed |
NCT01644773 -
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
|
Phase 1 | |
| Recruiting |
NCT02239952 -
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
|
N/A | |
| Completed |
NCT00565721 -
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
|
Phase 2 | |
| Recruiting |
NCT05929456 -
Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)
|
Phase 1 | |
| Recruiting |
NCT04552756 -
Seizures During Radiotherapy for High-grade Gliomas
|
N/A | |
| Not yet recruiting |
NCT04482933 -
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
|
Phase 2 | |
| Terminated |
NCT04730349 -
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT05873946 -
Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
|
||
| Recruiting |
NCT02848794 -
Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06209567 -
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
|
Early Phase 1 | |
| Not yet recruiting |
NCT06201351 -
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
|
||
| Recruiting |
NCT06118723 -
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
|
||
| Completed |
NCT00624728 -
Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04851834 -
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04908267 -
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
|
||
| Completed |
NCT03458312 -
Nurse-led Family and Network Consultations
|
N/A |